Kura Oncology, Inc. (KURA) Financials
KURA Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 448.9 million | 51.7 million |
2023-09-30 | 473.8 million | 43.8 million |
2023-06-30 | 494.7 million | 11.2 million |
2023-03-31 | 426.0 million | 30.8 million |
KURA Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -34.3 million | 7.2 million |
2023-09-30 | -29.0 million | 7.1 million |
2023-06-30 | -25.7 million | 7.0 million |
2023-03-31 | -35.9 million | 6.8 million |
KURA Net Income
No data available :(
KURA Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 424.0 million | - | 7.9 million |
2023-09-30 | 452.6 million | - | 8.1 million |
2023-06-30 | 477.0 million | - | 3.8 million |
2023-03-31 | 405.9 million | 9.2 million | 4.3 million |
KURA Shares Outstanding
KURA Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 16000 | 32.5 million | 14.2 million | 214000 |
2023-09-30 | 20000 | 29.3 million | 13.1 million | - |
2023-06-30 | 96000 | 28.2 million | 11.8 million | - |
2023-03-31 | 36000 | 25.2 million | 11.4 million | - |
KURA Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 1.3 million | 214000 |
2023-09-30 | - | 216000 |
2023-06-30 | - | 213000 |
2023-03-31 | - | 206000 |
KURA
Price: $20.28
52 week price:
Earnings Per Share: -2.08 USD
P/E Ratio: -10.46
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 495600
Ebitda: -9.1 millionMarket Capitalization: 1.6 billion